Aprepitant triple therapy for the prevention of chemotherapy-induced nausea and vomiting following high-dose cisplatin in Chinese patients: a randomized, double-blind, placebo-controlled phase III trial
详细信息 查看全文
- 作者：Zhihuang Hu (1) (2)
Ying Cheng (3)
Hongyu Zhang (4)
Caicun Zhou (5)
Baohui Han (6)
Yiping Zhang (7)
Cheng Huang (8)
Jianhua Chang (9)
Xiangqun Song (10)
Jun Liang (11)
Houjie Liang (12)
Chunxue Bai (13)
Shiying Yu (14)
Jia Chen (15)
Jie Wang (16)
Hongming Pan (17)
Denesh K. Chitkara (18)
Darcy A. Hille (18)
Li Zhang (1) (2) - 关键词：Nausea ; Emesis ; Aprepitant ; Emetogenic chemotherapy ; Standard antiemetic treatment
- 刊名：Supportive Care in Cancer
- 出版年：2014
- 出版时间：April 2014
- 年：2014
- 卷：22
- 期：4
- 页码：979-987
- 全文大小：346 KB
- 参考文献：1. Hesketh PJ (2008) Chemotherapy-induced nausea and vomiting. N Engl J Med 358:2482-494 CrossRef
2. Cohen L, de Moor CA, Eisenberg P et al (2007) Chemotherapy-induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settings. Support Care Cancer 15:497-03 CrossRef
3. Laszlo J, Lucas VS Jr (1981) Emesis as a critical problem in chemotherapy. N Engl J Med 305:948-49 CrossRef
4. Fernandez-Ortega P, Caloto MT, Chirveches E et al (2012) Chemotherapy-induced nausea and vomiting in clinical practice: impact on patients-quality of life. Support Care Cancer 20:3141-148 CrossRef
5. Warr D (2012) Management of highly emetogenic chemotherapy. Curr Opin Oncol 24:371-75 CrossRef
6. Grunberg SM, Deuson RR, Mavros P et al (2004) Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer 100:2261-268 CrossRef
7. Hargreaves R, Ferreira JC, Hughes D et al (2011) Development of aprepitant, the first neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting. Ann N Y Acad Sci 1222:40-8 CrossRef
8. Diemunsch P, Joshi GP, Brichant JF (2009) Neurokinin-1 receptor antagonists in the prevention of postoperative nausea and vomiting. Br J Anaesth 103:7-3 CrossRef
9. Navari RM, Reinhardt RR, Gralla RJ et al (1999) Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group. N Engl J Med 340:190-95 CrossRef
10. Campos D, Pereira JR, Reinhardt RR et al (2001) Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone. J Clin Oncol 19:1759-767
11. Hesketh PJ, Grunberg SM, Gralla RJ et al (2003) The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin—the Aprepitant Protocol 052 Study Group. J Clin Oncol 21:4112-119 CrossRef
12. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD et al (2003) Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 97:3090-098 CrossRef
13. de Wit R, Herrstedt J, Rapoport B et al (2003) Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy. J Clin Oncol 21:4105-111 CrossRef
14. Herrstedt J, Muss HB, Warr DG et al (2005) Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy. Cancer 104:1548-555 CrossRef
15. Yeo W, Mo FK, Suen JJ et al (2009) A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy. Breast Cancer Res Treat 113:529-35 CrossRef
16. Takahashi T, Hoshi E, Takagi M et al (2010) Multicenter, phase II, placebo-controlled, double-blind, randomized study of aprepitant in Japanese patients receiving high-dose cisplatin. Cancer Sci 101:2455-461 CrossRef
17. McCrea JB, Majumdar AK, Goldberg MR et al (2003) Effects of the neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone. Clin Pharmacol Ther 74:17-4 CrossRef
18. Boogaerts JG, Vanacker E, Seidel L et al (2000) Assessment of postoperative nausea using a visual analogue scale. Acta Anaesthesiol Scand 44:470-74 CrossRef
19. Martin AR, Pearson JD, Cai B et al (2003) Assessing the impact of chemotherapy-induced nausea and vomiting on patients-daily lives: a modified version of the Functional Living Index-Emesis (FLIE) with 5-day recall. Support Care Cancer 11:522-27 CrossRef
20. Decker GM, DeMeyer ES, Kisko DL (2006) Measuring the maintenance of daily life activities using the functional living index-emesis (FLIE) in patients receiving moderately emetogenic chemotherapy. J Support Oncol 4:35-1, 52
21. Martin AR, Carides AD, Pearson JD et al (2003) Functional relevance of antiemetic control: experience using the FLIE questionnaire in a randomised study of the NK-1 antagonist aprepitant. Eur J Cancer 39:1395-401 CrossRef
22. Feyer P, Jordan K (2011) Update and new trends in antiemetic therapy: the continuing need for novel therapies. Ann Oncol 22:30-8 CrossRef
23. Aapro M, Molassiotis A, Dicato M et al (2012) The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER). Ann Oncol 23:1986-992 CrossRef
24. Roila F, Herrstedt J, Aapro M et al (2010) Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 21(Suppl 5):v232–v243 CrossRef
25. Basch E, Prestrud AA, Hesketh PJ et al (2011) Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 29:4189-198 CrossRef
26. Ettinger DS, Armstrong DK, Barbour S et al (2012) Antiemesis. J Natl Compr Cancer Netw 10:456-85
27. Jordan K, Hinke A, Grothey A et al (2007) A meta-analysis comparing the efficacy of four 5-HT3-receptor antagonists for acute chemotherapy-induced emesis. Support Care Cancer 15:1023-033 CrossRef
28. Billio A, Morello E, Clarke MJ (2010) Serotonin receptor antagonists for highly emetogenic chemotherapy in adults. Cochrane Database Syst Rev. doi:10.1002/14651858.CD006272.pub2 , CD006272
29. del Giglio A, Soares HP, Caparroz C et al (2000) Granisetron is equivalent to ondansetron for prophylaxis of chemotherapy-induced nausea and vomiting: results of a meta-analysis of randomized controlled trials. Cancer 89:2301-308 CrossRef
30. Botrel TE, Clark OA, Clark L et al (2011) Efficacy of palonosetron (PAL) compared to other serotonin inhibitors (5-HT3R) in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic (MoHE) treatment: systematic review and meta- analysis. Support Care Cancer 19:823-32 CrossRef
31. Olver IN (1996) Antiemetic study methodology: recommendations for future studies. Oncology 53(Suppl 1):96-01 CrossRef
32. Longo F, Mansueto G, Lapadula V et al (2012) Combination of aprepitant, palonosetron and dexamethasone as antiemetic prophylaxis in lung cancer patients receiving multiple cycles of cisplatin-based chemotherapy. Int J Clin Pract 66:753-57 CrossRef - 作者单位：Zhihuang Hu (1) (2)
Ying Cheng (3)
Hongyu Zhang (4)
Caicun Zhou (5)
Baohui Han (6)
Yiping Zhang (7)
Cheng Huang (8)
Jianhua Chang (9)
Xiangqun Song (10)
Jun Liang (11)
Houjie Liang (12)
Chunxue Bai (13)
Shiying Yu (14)
Jia Chen (15)
Jie Wang (16)
Hongming Pan (17)
Denesh K. Chitkara (18)
Darcy A. Hille (18)
Li Zhang (1) (2)
1. Department of Medical Oncology, Sun Yat-sen University Cancer Center, 651 Dongfeng Road East, Guangzhou, 510060, People’s Republic of China
2. State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, 651 Dongfeng Road East, Guangzhou, 510060, People’s Republic of China
3. The first Department of Internal Medicine, Jilin Province Cancer Hospital, Changchun, People’s Republic of China
4. Department of Oncology, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, People’s Republic of China
5. Cancer Institute, Department of Oncology, Shanghai Pulmonary Hospital, Medical School, Tongji University, 507 Zhengmin Road, Shanghai, 200433, People’s Republic of China
6. Department of Pulmonary Medicine, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, 200030, People’s Republic of China
7. Department of Chemotherapy, Zhejiang Cancer Hospital, Hangzhou, 310022, People’s Republic of China
8. Department of Medical Oncology, Fujian Provincial Cancer Hospital, The Teaching Hospital of Fujian Medical University, Fuzhou, People’s Republic of China
9. Department of Medical Oncology, Fudan University Shanghai Cancer Center, 270 Dongan Road, Shanghai, 200032, People’s Republic of China
10. Department of Chemotherapy, Guangxi Zhuang Autonomous Region Tumor Hospital, Nanning, People’s Republic of China
11. Department of Medical Oncology, the Affiliated Hospital of Medical College, Qingdao University, Qingdao, People’s Republic of China
12. Department of Oncology, Southwest Hospital, Third Military Medical University, Chongqing, People’s Republic of China
13. Department of Pulmonary Medicine, Zhongshan Hospital, Fudan University, 80 Feng Lin Rd, Shanghai, 200032, People’s Republic of China
14. Cancer Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430030, People’s Republic of China
15. Department of Medical Oncology, Jiangsu Cancer Hospital, No. 42 Baizi ting, Nanjing, 210009, Jiangsu Province, People’s Republic of China
16. Department of Thoracic Medical Oncology, Beijing Cancer Hospital, Beijing, People’s Republic of China
17. Department of Medical Oncology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, People’s Republic of China
18. Merck Sharp & Dohme Corp., Whitehouse Station, NJ, USA - ISSN：1433-7339
文摘
Purpose Aprepitant, an oral neurokinin-1 receptor antagonist, has demonstrated improved control of chemotherapy-induced nausea and vomiting (CINV) in previous studies. This is the first phase III study to evaluate the efficacy and tolerability of aprepitant in patients receiving highly emetogenic chemotherapy (HEC) in Asian countries. Methods This multicenter, double-blind, placebo-controlled trial assessed the prevention of CINV during the acute phase (AP), delayed phase (DP), and overall phase (OP). Patients receiving HEC were randomized to either an aprepitant group (day 1, aprepitant 125?mg; days 2-, aprepitant 80?mg) or a standard therapy group (days 1-, placebo). Both groups received intravenous granisetron and oral dexamethasone. The primary end point was complete response (CR; no emesis and no use of rescue therapy) during the OP. Results Of the 421 randomized patients, 411 (98?%) were assessable for efficacy; 69.6?% (142/204) and 57.0?% (118/207) of patients reported CR during the OP in the aprepitant and standard therapy groups, respectively (P--.007). CR rates in the aprepitant group were higher during the DP (74.0?% vs. 59.4?%, P--.001) but were similar during the AP (79.4?% vs. 79.3?%, P--.942). Toxicity and adverse events were comparable in both groups. Conclusions The addition of aprepitant to standard antiemetic treatment regimens for Chinese patients undergoing HEC provided superior CINV prevention and was well tolerated.